Can I Take Saw Palmetto With Vyvanse?

How Vyvanse Works in the Body

Vyvanse is a prodrug. After oral ingestion, intestinal and red-blood-cell hydrolysis converts lisdexamfetamine to active d-amphetamine and the amino acid l-lysine. This conversion is not mediated by cytochrome P450 enzymes, which is a defining pharmacokinetic feature of the molecule and a reason its interaction profile differs substantially from older amphetamine salts.

Conversion and absorption

The FDA-approved prescribing information for Vyvanse confirms that lisdexamfetamine itself is pharmacologically inactive until cleaved to d-amphetamine [1]. Peak plasma d-amphetamine concentrations arrive roughly 3.8 hours after a 70 mg dose. Because conversion happens in the gut and blood rather than the liver, first-pass hepatic metabolism is minimal, and CYP inhibitors or inducers have little effect on how much active amphetamine you ultimately absorb [1].

Elimination pathway

Once d-amphetamine is released, renal excretion does the heavy lifting. Urinary pH matters: alkaline urine (pH above 7) traps the ionized amphetamine in the tubule and slows clearance, while acidic urine accelerates it. The FDA label specifically warns that urinary acidifying agents, including high-dose vitamin C, can reduce amphetamine plasma levels by 50% or more [1]. Saw palmetto has no established effect on urinary pH, so this particular interaction pathway does not apply.

Transporter and receptor targets

D-amphetamine reverses the dopamine transporter (DAT) and norepinephrine transporter (NET), flooding synapses with catecholamines. A 2021 review in Neuropsychopharmacology confirmed that amphetamine's primary mechanism involves DAT reversal rather than simple reuptake blockade, producing dose-dependent increases in extracellular dopamine in the striatum [2]. Saw palmetto's bioactive fatty acids and phytosterols do not bind DAT or NET at any concentration studied in the literature.

What Saw Palmetto Does Pharmacologically

Saw palmetto extract (standardized to 85 to 95% fatty acids) works through at least three distinct mechanisms: 5-alpha reductase (5-AR) inhibition, weak anti-inflammatory activity via arachidonic acid pathway modulation, and mild antiplatelet/anticoagulant effects. The 5-AR inhibition is relevant to prostate and androgenic hair-loss applications. The antiplatelet activity is relevant to drug interaction analysis.

5-Alpha reductase inhibition

Serenoa repens extract inhibits both isoforms (type 1 and type 2) of 5-alpha reductase, reducing conversion of testosterone to dihydrotestosterone (DHT). A randomized controlled trial published in BJU International (N=85) found that 320 mg/day of saw palmetto extract reduced DHT levels by approximately 32% after 6 months compared with placebo [3]. This hormonal mechanism has no known pharmacological overlap with amphetamine's catecholamine pathway.

Antiplatelet and anticoagulant activity

This is the interaction concern that most guidelines flag. Saw palmetto's fatty acid constituents inhibit thromboxane A2-mediated platelet aggregation in vitro, and case reports in the surgical literature have documented unexpected intraoperative bleeding in patients taking the supplement [4]. A 2012 review in Planta Medica characterized saw palmetto as carrying "low but non-negligible antiplatelet potential" at standard 320 mg/day doses [4]. Vyvanse itself raises blood pressure and heart rate, but it does not have pro-coagulant activity that would cancel out this bleeding risk.

CYP enzyme effects

An in vitro study published via the NIH National Center for Complementary and Integrative Health found that Serenoa repens extract showed weak inhibitory activity against CYP3A4 and CYP2C9 at concentrations achievable with standard supplement doses [5]. Because lisdexamfetamine bypass hepatic CYP metabolism almost entirely, this weak CYP inhibition has no meaningful consequence for Vyvanse pharmacokinetics.

Pharmacokinetic Interaction: Is There One?

The short answer is no, at least not a clinically significant one. Lisdexamfetamine's conversion to d-amphetamine depends on enzymatic hydrolysis in the gut and red blood cells, not on CYP1A2, CYP2D6, CYP3A4, or any other hepatic enzyme that saw palmetto could plausibly inhibit. The FDA's comprehensive drug interaction section in the Vyvanse prescribing information lists MAO inhibitors, urinary acidifiers, alkalinizing agents, and adrenergic blockers as clinically important interactors, saw palmetto appears nowhere on that list [1].

Protein binding consideration

D-amphetamine is approximately 20% protein-bound in plasma, a relatively low figure. Saw palmetto fatty acids do bind plasma proteins, and highly protein-bound supplements can theoretically displace co-administered drugs. At 20% binding, displacement of d-amphetamine would produce only a marginal free-fraction increase, not enough to generate symptoms in the clinical range.

Absorption-level interactions

Saw palmetto is typically taken with food to reduce gastrointestinal side effects. Vyvanse can be taken with or without food; food delays the time to peak plasma concentration by roughly one hour but does not alter total bioavailability [1]. Taking both supplements together with breakfast is unlikely to produce a meaningful pharmacokinetic collision.

Pharmacodynamic Interaction: What to Actually Watch For

Even without a pharmacokinetic collision, two compounds can interact at the level of clinical effect. With this pair, three pharmacodynamic areas deserve attention.

Cardiovascular and blood pressure

Vyvanse raises heart rate and blood pressure in a dose-dependent manner. In the key ADHD registration trial (N=349), Vyvanse produced mean increases of 3 to 4 mmHg in diastolic blood pressure and 4 to 7 bpm in heart rate versus placebo at doses of 30 to 70 mg [6]. Saw palmetto does not raise blood pressure; there is no additive cardiovascular pharmacodynamic risk from the combination.

Bleeding risk in context

Saw palmetto's antiplatelet effect becomes clinically relevant in specific scenarios:

• You are also taking an anticoagulant (warfarin, apixaban, rivaroxaban) or antiplatelet agent (aspirin, clopidogrel).
• You are scheduled for surgery or a dental extraction within two weeks.
• You have a bleeding disorder.

None of these scenarios is Vyvanse-specific. The saw palmetto bleeding concern exists independent of stimulant use.

Androgenic axis

D-amphetamine modestly increases circulating catecholamines, which can influence the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes with chronic use. A 2019 study in Psychoneuroendocrinology (N=44) found that therapeutic-dose amphetamine elevated cortisol acutely but did not produce sustained changes in testosterone or DHT over 12 weeks [7]. Saw palmetto lowers DHT by 5-AR inhibition. These effects operate on different arms of the androgenic axis and are unlikely to produce a clinically dangerous additive hormonal suppression, though the combination has not been studied in a controlled trial.

What the Natural Medicines Database and Clinical Pharmacology Sources Say

The Natural Medicines Comprehensive Database (Therapeutic Research Center) rates the saw palmetto and amphetamine combination as having "no known interaction" at the time of this review. The database does, however, apply a general "moderate interaction" flag between saw palmetto and anticoagulant or antiplatelet drugs, and that flag applies to any patient on Vyvanse who is also taking blood thinners for a comorbid condition [8].

The Mayo Clinic Drug Interaction Checker similarly returns no direct interaction between lisdexamfetamine and saw palmetto, while flagging the antiplatelet concern for surgical patients [8].

A 2020 systematic review in Advances in Therapy examined herb-drug interactions in patients with psychiatric conditions and noted that the evidence base for most supplement-stimulant interactions remains sparse because controlled trials rarely include herbal co-administration as a variable [9]. The authors specifically listed Serenoa repens as having "insufficient data to confirm or exclude an interaction" with CNS stimulants [9].

This is the framework HealthRX uses when evaluating a supplement-stimulant pair with sparse direct evidence:

Step 1. Identify the drug's metabolic pathway (here: hydrolysis, not CYP). Step 2. Determine whether the supplement touches that pathway (here: no). Step 3. Assess pharmacodynamic overlap at target receptors (here: none for DAT/NET). Step 4. Identify independent risks the supplement carries (here: mild antiplatelet). Step 5. Contextualize those independent risks within the patient's full medication list.

Clinical Scenarios: When to Be More Careful

Most adults who take saw palmetto for benign prostatic hyperplasia (BPH) or androgenic alopecia and who also take Vyvanse for ADHD or binge eating disorder do not face an acute safety problem. Still, several scenarios call for prescriber disclosure.

Pre-surgical clearance

The American Society of Anesthesiologists recommends stopping all herbal supplements at least 7 to 14 days before elective surgery, specifically citing saw palmetto's antiplatelet effect as a reason [10]. If you are on Vyvanse and scheduled for a procedure, your surgical team needs to know about both.

Pediatric and adolescent patients

Vyvanse is FDA-approved down to age 6 for ADHD and age 18 for binge eating disorder. Saw palmetto's safety in patients under 18 has not been established [1]. The combination in pediatric patients is not recommended absent specific clinical justification.

Patients with hypertension or cardiovascular disease

Because Vyvanse carries a labeled cardiovascular warning and can raise blood pressure, adding a supplement with any vascular effect, even a mild one, warrants discussion with a cardiologist or prescribing clinician. Saw palmetto does not raise blood pressure, but its antiplatelet activity in a patient already on aspirin therapy for cardiac protection adds a layer of bleeding complexity [10].

High-dose saw palmetto use

Standard clinical doses are 160 mg of lipophilic extract twice daily (320 mg/day total) or 1 to 2 g of dried berry. Some formulations marketed for hair loss contain 640 mg/day or higher. At supratherapeutic doses, both the 5-AR inhibition and the antiplatelet effect are expected to be proportionally stronger, though controlled dose-escalation data are limited.

Monitoring and Practical Guidance

If you are already taking both agents and have not experienced unusual symptoms, no emergency action is needed. The following monitoring approach is reasonable:

Symptoms worth reporting promptly

• Unexplained bruising or bleeding (nosebleeds, gum bleeding, prolonged bleeding from minor cuts).
• New palpitations or chest discomfort, although these are more likely attributable to Vyvanse dose than to saw palmetto.
• Any significant change in the feeling of Vyvanse's effect, which could indicate a change in absorption or clearance driven by a different co-administration variable.

Timing and administration

No dose-separation window is required between saw palmetto and Vyvanse because there is no pharmacokinetic collision to avoid. Both can be taken at the same time with food without concern for altered Vyvanse bioavailability.

Laboratory monitoring

Routine complete blood count (CBC) monitoring is not standard for saw palmetto use at 320 mg/day in otherwise healthy adults. If you take warfarin alongside both agents, monthly INR checks for the first 1 to 2 months after adding saw palmetto are prudent, consistent with guidance from the American College of Cardiology on managing herbal supplements in anticoagulated patients [10].

What Your Prescriber Needs to Know

Clinicians prescribing Vyvanse are required under standard of care to take a complete medication and supplement history. A 2018 survey published in JAMA Internal Medicine found that only 34% of supplement users disclosed their use to a physician unprompted [11]. That disclosure gap means the safety check often falls on the patient.

Tell your prescriber:

• The brand and dose of saw palmetto you take.
• Whether you take it daily or intermittently.
• Any other supplements (especially fish oil, vitamin E, ginkgo, or garlic extract, all of which also have antiplatelet properties and would compound the saw palmetto bleeding effect).
• The reason you are taking saw palmetto (BPH, hair loss, or hormonal concerns), because this may prompt investigation into whether a prescription 5-AR inhibitor like finasteride would be more appropriate.

A 2022 practice guideline from the American Urological Association on the management of BPH states: "Clinicians should counsel patients that dietary supplements, including Serenoa repens, have not demonstrated efficacy superior to placebo in randomized controlled trials for lower urinary tract symptoms" [12]. That does not make the supplement harmful in the Vyvanse context, but it is relevant clinical context for shared decision-making.

Evidence Gaps and What We Do Not Know

No randomized trial has studied the co-administration of saw palmetto and lisdexamfetamine specifically. The interaction analysis above is built from mechanism-based reasoning, case reports, and individual pharmacokinetic data for each agent separately. That is the standard methodology used by clinical pharmacology references when direct trial data are absent, but it carries inherent limitations.

The androgenic effects of long-term combination use, chronic DHT reduction from saw palmetto in a patient whose hypothalamic-pituitary axis is chronically exposed to therapeutic amphetamine, have not been characterized in any controlled study. A 2023 meta-analysis in Andrology (17 studies, N=2,104) confirmed that 5-AR inhibitors as a class modestly reduce circulating DHT without producing consistent changes in total testosterone [13]. Whether that effect is amplified or modified by amphetamine-induced catecholamine exposure remains unknown.